Avid Bioservices Inc (CDMO)

[dia76ca]

Listen carefully to what the CFO said!

"Along with the work being done for our third-party clients, Avid continues to be an -- instrumental in providing drug supply for the bavituximab Phase III trial WHILE ALSO preparing bavituximab for potential COMMERCIALIZATION.

Now turning to our cash position. We continued to maintain a balanced financial approach, ending the quarter with $41.6 million in cash compared to $35.2 million in cash at fiscal year end, April 30, 2013. This provides us sufficient capital to fund our operations through at least the first quarter of fiscal year '15 based on our current financial projections, giving us the needed flexibility to initiate the upcoming Phase III trial in second-line lung cancer while STRENGTHENING OUR POSITION as we evaluate other opportunities, including ongoing PARTNERING discussions."

These statements leave a lot of doors open!